大葉大學圖書館 |

Pharmaceutical markets and insurance worldwide[electronic resource] /

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
杜威分類號:	338.47615
書名/作者:	Pharmaceutical markets and insurance worldwide/ edited by Avi Dor.
其他作者:	Dor, Avi,
出版者:	Bingley, UK : : Emerald,, 2010.
面頁冊數:	1 online resource (410 p.)
標題:	Medical economics.
標題:	Health insurance - Finance.
標題:	Health insurance - Costs.
標題:	Pharmaceutical industry - Economic aspects.
ISBN:	9781849507172 (ebook)
ISBN:	1849507171 (ebook)
書目註:	Includes bibliographical references.
內容註:	Overview / Avi Dor -- Part I: International reviews. Pharmaceutical policies in European countries / Pedro Pita Barros -- International experience with comparative effectiveness research: case studies from England/Wales and Germany / John F.P. Bridges, Joshua P. Cohen, Peter G. Grist and Axel C. M±élbacher -- Part II: National case studies. Pharmaceutical policy in the Netherlands: from price regulation towards managed competition / Lieke H.H.M. Boonen, Stéphanie A. van der Geest, Frederik T. Schut and Marco Varkevisser -- Impact of pharmaceutical regulation and policies on health system performance goals in Israel / Philip Sax and Amir Shmueli -- Global budgets and provider incentives: hospitals' drug expenditures in Taiwan / Shin-Yi Chou, Mary E. Deily, Hsien-Ming Lien and Jing Hua Zhang -- Medicare Part D turns four: trends in plan design, enrollment, and the impact of the program on beneficiaries / Jack Hoadley and Kosali Simon -- Part III: U.S. studies -- from markets to policy innovations. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes / William E. Encinosa, Didem Bernard and Avi Dor -- Cost sharing, benefit design, and adherence: the case of multiple sclerosis / Avi Dor, Maureen J. Lage, Marcy L. Tarrants and Jane Castelli-Haley -- Generic utilization and cost-sharing for prescription drugs / Teresa Bernard Gibson, Catherine G. McLaughlin and Dean G. Smith -- Drug prices, out-of-pocket payments, and insurer costs: how do payers vary? / Jie Chen and John A Rizzo -- Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions / Yuriy Pylypchuk -- The effect of drug vintage on survival: micro evidence from Puerto Rico's Medicaid program / Frank R. Lichtenberg -- Part IV: Special topics. Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era / Yang Xie, John M. Brooks, Julie M. Urmie and William R. Doucette -- Patents, innovation, and the welfare effects of Medicare Part D / Adam Gailey, Darius Lakdawalla and Neeraj Sood.
摘要、提要註:	The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries.
電子資源:	http://www.emeraldinsight.com/0731-2199/22

Pharmaceutical markets and insurance worldwide[electronic resource] /
Pharmaceutical markets and insurance worldwide[electronic resource] /edited by Avi Dor. - Bingley, UK :Emerald,2010. - 1 online resource (410 p.) - Advances in health economics and health services research,v. 220731-2199 ;. - Advances in health economics and health services research ;v. 16..

Includes bibliographical references.

Overview / Avi Dor -- Part I: International reviews. Pharmaceutical policies in European countries / Pedro Pita Barros -- International experience with comparative effectiveness research: case studies from England/Wales and Germany / John F.P. Bridges, Joshua P. Cohen, Peter G. Grist and Axel C. M±élbacher -- Part II: National case studies. Pharmaceutical policy in the Netherlands: from price regulation towards managed competition / Lieke H.H.M. Boonen, Stéphanie A. van der Geest, Frederik T. Schut and Marco Varkevisser -- Impact of pharmaceutical regulation and policies on health system performance goals in Israel / Philip Sax and Amir Shmueli -- Global budgets and provider incentives: hospitals' drug expenditures in Taiwan / Shin-Yi Chou, Mary E. Deily, Hsien-Ming Lien and Jing Hua Zhang -- Medicare Part D turns four: trends in plan design, enrollment, and the impact of the program on beneficiaries / Jack Hoadley and Kosali Simon -- Part III: U.S. studies -- from markets to policy innovations. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes / William E. Encinosa, Didem Bernard and Avi Dor -- Cost sharing, benefit design, and adherence: the case of multiple sclerosis / Avi Dor, Maureen J. Lage, Marcy L. Tarrants and Jane Castelli-Haley -- Generic utilization and cost-sharing for prescription drugs / Teresa Bernard Gibson, Catherine G. McLaughlin and Dean G. Smith -- Drug prices, out-of-pocket payments, and insurer costs: how do payers vary? / Jie Chen and John A Rizzo -- Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions / Yuriy Pylypchuk -- The effect of drug vintage on survival: micro evidence from Puerto Rico's Medicaid program / Frank R. Lichtenberg -- Part IV: Special topics. Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era / Yang Xie, John M. Brooks, Julie M. Urmie and William R. Doucette -- Patents, innovation, and the welfare effects of Medicare Part D / Adam Gailey, Darius Lakdawalla and Neeraj Sood.

The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries.

ISBN: 9781849507172 (ebook)Subjects--Topical Terms:

379453
Medical economics.

LC Class. No.: RA410 / .P53 2010

Dewey Class. No.: 338.47615

Pharmaceutical markets and insurance worldwide[electronic resource] /
LDR:03934nam a2200337Ka 4500 001 346341
003 OCoLC
005 20110601110448.0
006 m d
007 cr un|||||||||
008 111111s2010 enk ob 000 0 eng d
020 $a 9781849507172 (ebook)
020 $a 1849507171 (ebook)
035 $a (OCoLC)609429852
035 $a lc505081256
040 $a ZJC $b eng $c ZJC $d EBLCP $d YDXCP $d OCLCQ $d DHU
050 4 $a RA410 $b .P53 2010
072 7 $a KCQ $2 bicssc
072 7 $a KNDP $2 bicssc
072 7 $a BUS033040 $2 bisacsh
072 7 $a BUS000000 $2 bisacsh
072 7 $a MED071000 $2 bisacsh
082 0 4 $a 338.47615 $2 22
245 0 0 $a Pharmaceutical markets and insurance worldwide $h [electronic resource] / $c edited by Avi Dor.
260 $a Bingley, UK : $b Emerald, $c 2010.
300 $a 1 online resource (410 p.)
490 1 $a Advances in health economics and health services research, $x 0731-2199 ; $v v. 22
504 $a Includes bibliographical references.
505 0 $a Overview / Avi Dor -- Part I: International reviews. Pharmaceutical policies in European countries / Pedro Pita Barros -- International experience with comparative effectiveness research: case studies from England/Wales and Germany / John F.P. Bridges, Joshua P. Cohen, Peter G. Grist and Axel C. M±élbacher -- Part II: National case studies. Pharmaceutical policy in the Netherlands: from price regulation towards managed competition / Lieke H.H.M. Boonen, Stéphanie A. van der Geest, Frederik T. Schut and Marco Varkevisser -- Impact of pharmaceutical regulation and policies on health system performance goals in Israel / Philip Sax and Amir Shmueli -- Global budgets and provider incentives: hospitals' drug expenditures in Taiwan / Shin-Yi Chou, Mary E. Deily, Hsien-Ming Lien and Jing Hua Zhang -- Medicare Part D turns four: trends in plan design, enrollment, and the impact of the program on beneficiaries / Jack Hoadley and Kosali Simon -- Part III: U.S. studies -- from markets to policy innovations. Does prescription drug adherence reduce hospitalizations and costs? The case of diabetes / William E. Encinosa, Didem Bernard and Avi Dor -- Cost sharing, benefit design, and adherence: the case of multiple sclerosis / Avi Dor, Maureen J. Lage, Marcy L. Tarrants and Jane Castelli-Haley -- Generic utilization and cost-sharing for prescription drugs / Teresa Bernard Gibson, Catherine G. McLaughlin and Dean G. Smith -- Drug prices, out-of-pocket payments, and insurer costs: how do payers vary? / Jie Chen and John A Rizzo -- Adverse selection and the effect of health insurance on utilization of prescribed medicine among patients with chronic conditions / Yuriy Pylypchuk -- The effect of drug vintage on survival: micro evidence from Puerto Rico's Medicaid program / Frank R. Lichtenberg -- Part IV: Special topics. Retail pharmacy market structure and insurer-independent pharmacy bargaining in the Medicare Part D era / Yang Xie, John M. Brooks, Julie M. Urmie and William R. Doucette -- Patents, innovation, and the welfare effects of Medicare Part D / Adam Gailey, Darius Lakdawalla and Neeraj Sood.
520 $a The fields of pharmaceutical economics and health economics/policy are reaching a point of convergence. This is due to both the widespread availability of pharmaceutical treatments, accompanied by broader insurance coverage, and the regulation of prescription drugs in both private and government plans. This book will bridge the gap. We will explore developments in both U.S. and International setting. The system of the U.S. is characterized by a mix of private and government insurance for prescription drugs with the expansion of Medicare Part D. Most other developed countries are characterized by social insurance with either the government as a single payer such as in Canada or Australia, or a national health service as in many other European countries.
650 0 $a Medical economics. $3 379453
650 0 $a Health insurance $x Finance. $3 426088
650 0 $a Health insurance $x Costs. $3 426089
650 0 $a Pharmaceutical industry $x Economic aspects. $3 426090
700 1 $a Dor, Avi, $d 1956- $3 425871
776 1 $z 9781849507165
830 0 $a Advances in health economics and health services research ; $v v. 16. $3 400726
856 4 0 $u http://www.emeraldinsight.com/0731-2199/22